Newsletter
On 22 March 2026, India’s pharmaceutical market witnessed a decisive shift that had been building quietly for months. Within just 48 hours of semaglutide losing patent protection, more than fifteen generic versions of the drug entered the market. Prices dropped sharply, in some cases by as much as 70- 90%. What was once a premium therapy priced above ₹10,000 per month suddenly became available at a fraction of the cost.
At first glance, this may look like a typical generic entry story. But this moment carries far deeper implications. It marks the beginning of a shift in how India approaches the treatment of two of its fastest-growing health challenges: diabetes and obesity.
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists. These drugs help regulate blood sugar, increase satiety, and slow gastric emptying. In practical terms, they not only help manage Type 2 diabetes but also support weight loss. This dual benefit is what has made semaglutide one of the most talked-about drugs globally in recent years. Internationally, brands like Ozempic and Wegovy have driven massive demand, turning the category into a multi-billion dollar opportunity.
In India, however, access remained limited for a long time. Novo Nordisk, which held the patent, priced its products at levels that restricted usage to a relatively small segment of patients. Monthly treatment costs ranged between ₹8,800 and ₹16,400. For a country where long-term therapy affordability plays a critical role in adherence, this created a clear gap between clinical potential and real-world access.
The patent expiry has now changed that equation.
Indian pharmaceutical companies were well prepared for this transition. Firms such as Sun Pharma, Zydus Lifesciences, Dr Reddy’s Laboratories, Torrent Pharma, Alkem Labs, Glenmark, Natco Pharma, and Eris Lifesciences entered the market almost immediately.
Many of these companies had spent months aligning their manufacturing, regulatory approvals, and distribution strategies in anticipation of this moment. Partnerships further strengthened their position. Zydus collaborated with Lupin for co-marketing, while Natco partnered with Eris Lifesciences, ensuring broader reach from the outset.
The most visible outcome of this rapid entry has been the sharp correction in pricing. Several generic versions are now available in the ₹1,300 to ₹5,000 per month range, depending on the brand and delivery format. Natco’s offering, for instance, is priced close to ₹1,290 per month, while other players such as Glenmark and Alkem are operating in a similar low-cost bracket. Even relatively premium generic offerings remain significantly cheaper than the innovator products.
This price correction is not merely a competitive response. It fundamentally expands the addressable market. India currently has over 100 million people living with diabetes, along with a rapidly increasing number of individuals dealing with obesity and related metabolic conditions. Despite this, the GLP-1 therapy market in India has remained relatively small, estimated at around ₹1,400 crore prior to generic entry. High costs were the primary constraint.
With affordability improving, that constraint is beginning to ease. Market estimates now suggest that the GLP-1 segment could grow to nearly ₹12,000 crore by 2030. This expansion will not be driven only by price reductions, but by increased adoption, earlier intervention, and longer treatment duration.
However, this is not a straightforward commoditisation story. The competition is evolving across multiple dimensions.
One of the most important differentiators is the method of delivery. Companies are introducing semaglutide in various formats, including pre-filled injectable pens, reusable pen systems, dose-specific vials, and oral tablets. Each format comes with its own advantages and limitations in terms of convenience, cost, and patient adherence.
For instance, injectable pens offer ease of use but may be priced higher, while vials provide a lower-cost alternative but require more handling. Oral formulations, such as those introduced by Torrent Pharma, could significantly expand adoption among patients who are hesitant about injections.
This diversification indicates that companies are not competing solely on price. They are also competing on usability, patient experience, and long-term adherence outcomes.
Another layer of complexity lies in regulatory approvals. Not all generic versions of semaglutide currently have approval for both diabetes and obesity indications. Some products are approved only for diabetes management. However, in clinical practice, physicians may prescribe these drugs off-label for weight management, especially given the growing demand for obesity treatment. This creates a nuanced landscape where formal regulatory positioning and real-world usage may diverge.
Meanwhile, Novo Nordisk’s response has been measured. The company has indicated that it does not intend to engage in an aggressive price war immediately. Instead, it appears to be focusing on maintaining its premium positioning through clinical credibility, brand trust, and established physician relationships. This approach reflects confidence in its long-term strategy, but it also introduces uncertainty about how much market share it can retain in a highly price-sensitive environment.
Beyond pharmaceutical companies, the ripple effects of this transition are beginning to appear across the broader healthcare ecosystem. Hospitals, endocrinology clinics, and obesity management centres are preparing for increased patient inflow. Telemedicine platforms are likely to see higher consultation volumes related to metabolic health. As therapy becomes more accessible, the entire care delivery model around diabetes and obesity may evolve.
This shift also introduces new challenges. With an expected influx of 40 to 50 brands in the coming months, the market risks becoming crowded. Differentiation could become difficult, leading to increased reliance on physician relationships, distribution networks, and patient support programs. Ensuring consistent quality and supply will be critical, particularly in a category that requires long-term adherence.
In many ways, this development reflects a familiar pattern in India’s pharmaceutical landscape. The country has repeatedly demonstrated its ability to take high-cost, patented therapies and make them widely accessible through generics. However, the scale and impact of semaglutide may be significantly larger than previous examples, given the size of the underlying health challenges it addresses.
What is unfolding today is not just a pricing shift or a competitive realignment. It is the beginning of a broader transition in how chronic metabolic conditions are treated in India. As affordability improves and access expands, semaglutide could move from being a niche therapy to a mainstream treatment option.
This moment, therefore, is not defined by the number of generic launches or the extent of price reduction. It is defined by the possibility that a previously limited therapy is now within reach for a much larger population. And in a country facing a growing burden of diabetes and obesity, that shift carries implications that extend well beyond the pharmaceutical industry.
